226 related articles for article (PubMed ID: 37627546)
1. Preventative and Therapeutic Effects of Astaxanthin on NAFLD.
Sayuti NH; Muhammad Nawawi KN; Goon JA; Mokhtar NM; Makpol S; Tan JK
Antioxidants (Basel); 2023 Aug; 12(8):. PubMed ID: 37627546
[TBL] [Abstract][Full Text] [Related]
2. Prevention of NAFLD/NASH by Astaxanthin and β-Cryptoxanthin.
Ota T
Adv Exp Med Biol; 2021; 1261():231-238. PubMed ID: 33783746
[TBL] [Abstract][Full Text] [Related]
3. Novel Action of Carotenoids on Non-Alcoholic Fatty Liver Disease: Macrophage Polarization and Liver Homeostasis.
Ni Y; Zhuge F; Nagashimada M; Ota T
Nutrients; 2016 Jun; 8(7):. PubMed ID: 27347998
[TBL] [Abstract][Full Text] [Related]
4. Health Benefits of Carotenoids: A Role of Carotenoids in the Prevention of Non-Alcoholic Fatty Liver Disease.
Lee Y; Hu S; Park YK; Lee JY
Prev Nutr Food Sci; 2019 Jun; 24(2):103-113. PubMed ID: 31328113
[TBL] [Abstract][Full Text] [Related]
5. Astaxanthin prevents and reverses diet-induced insulin resistance and steatohepatitis in mice: A comparison with vitamin E.
Ni Y; Nagashimada M; Zhuge F; Zhan L; Nagata N; Tsutsui A; Nakanuma Y; Kaneko S; Ota T
Sci Rep; 2015 Nov; 5():17192. PubMed ID: 26603489
[TBL] [Abstract][Full Text] [Related]
6. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
[TBL] [Abstract][Full Text] [Related]
7. The Potential of Non-Provitamin A Carotenoids for the Prevention and Treatment of Non-Alcoholic Fatty Liver Disease.
Murillo AG; DiMarco DM; Fernandez ML
Biology (Basel); 2016 Nov; 5(4):. PubMed ID: 27834813
[TBL] [Abstract][Full Text] [Related]
8. Herbal Medicine in the Treatment of Non-Alcoholic Fatty Liver Diseases-Efficacy, Action Mechanism, and Clinical Application.
Xu Y; Guo W; Zhang C; Chen F; Tan HY; Li S; Wang N; Feng Y
Front Pharmacol; 2020; 11():601. PubMed ID: 32477116
[TBL] [Abstract][Full Text] [Related]
9. Micronutrient Antioxidants and Nonalcoholic Fatty Liver Disease.
Chen G; Ni Y; Nagata N; Xu L; Ota T
Int J Mol Sci; 2016 Aug; 17(9):. PubMed ID: 27563875
[TBL] [Abstract][Full Text] [Related]
10. Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention.
Tacke F; Weiskirchen R
Ann Transl Med; 2021 Apr; 9(8):729. PubMed ID: 33987427
[TBL] [Abstract][Full Text] [Related]
11. Non-alcoholic fatty liver disease: An overview of risk factors, pathophysiological mechanisms, diagnostic procedures, and therapeutic interventions.
Gerges SH; Wahdan SA; Elsherbiny DA; El-Demerdash E
Life Sci; 2021 Apr; 271():119220. PubMed ID: 33592199
[TBL] [Abstract][Full Text] [Related]
12. Astaxanthin Prevents Diet-Induced NASH Progression by Shaping Intrahepatic Immunity.
Yang M; Kimchi ET; Staveley-O'Carroll KF; Li G
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681695
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults.
Vernon G; Baranova A; Younossi ZM
Aliment Pharmacol Ther; 2011 Aug; 34(3):274-85. PubMed ID: 21623852
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant supplements for non-alcoholic fatty liver disease and/or steatohepatitis.
Lirussi F; Azzalini L; Orando S; Orlando R; Angelico F
Cochrane Database Syst Rev; 2007 Jan; 2007(1):CD004996. PubMed ID: 17253535
[TBL] [Abstract][Full Text] [Related]
15. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
Ota T
Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
[TBL] [Abstract][Full Text] [Related]
16. Phytotherapy as Multi-Hit Therapy to Confront the Multiple Pathophysiology in Non-Alcoholic Fatty Liver Disease: A Systematic Review of Experimental Interventions.
Ore A; Akinloye OA
Medicina (Kaunas); 2021 Aug; 57(8):. PubMed ID: 34441028
[TBL] [Abstract][Full Text] [Related]
17. Astaxanthin in Liver Health and Disease: A Potential Therapeutic Agent.
Li J; Guo C; Wu J
Drug Des Devel Ther; 2020; 14():2275-2285. PubMed ID: 32606597
[TBL] [Abstract][Full Text] [Related]
18. A Review of the Effects of Fucoxanthin on NAFLD.
Sayuti NH; Muhammad Nawawi KN; Goon JA; Mokhtar NM; Makpol S; Tan JK
Nutrients; 2023 Apr; 15(8):. PubMed ID: 37111187
[TBL] [Abstract][Full Text] [Related]
19. A Review Of Current And Upcoming Treatment Modalities In Non-Alcoholic Fatty Liver Disease And Non-Alcoholic Steatohepatitis.
Ganguli S; DeLeeuw P; Satapathy SK
Hepat Med; 2019; 11():159-178. PubMed ID: 31814783
[TBL] [Abstract][Full Text] [Related]
20. Macrophage-derived thrombospondin 1 promotes obesity-associated non-alcoholic fatty liver disease.
Gwag T; Reddy Mooli RG; Li D; Lee S; Lee EY; Wang S
JHEP Rep; 2021 Feb; 3(1):100193. PubMed ID: 33294831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
